文献速递主动脉疾病

医生改良开窗/分支支架治疗症状性复杂主动脉病变或包裹性破裂的结果

Outcome of Surgeon-Modified Fenestrated/Branched Stent-Grafts for Symptomatic Complex Aortic Pathologies or Contained Rupture.
PubMed 文献 · J Endovasc Ther · 2017-09-06

单中心回顾性分析21例高危症状性复杂主动脉病变或包裹性破裂患者,采用医生改良开窗/分支支架治疗,技术成功率100%,围术期死亡3例,随访期间靶血管通畅,但存在内漏及脊髓损伤等并发症。

要点

  • 医生改良开窗/分支支架可用于不适合市售支架的复杂主动脉病变紧急治疗。
  • 技术成功率100%,但围术期死亡3例,需警惕脊髓损伤和肾功能衰竭。
  • 随访中靶 renovisceral 血管均通畅,但内漏发生率较高。

核心结论

  • 医生改良开窗/分支支架可用于高危复杂腹主动脉及胸腹主动脉病变的紧急治疗,尤其适用于解剖不适合市售支架的患者。

研究设计与样本

  • 单中心回顾性分析2014年4月至2016年9月连续21例接受医生改良开窗/分支支架治疗的患者,平均年龄70岁(范围58-87),男性16例。
  • 适应证包括11例胸腹主动脉病变和10例肾旁主动脉病变,其中8例表现为症状性,13例为包裹性破裂。
  • 平均动脉瘤直径7.4±2.3 cm。

主要发现

  • 技术成功率为100%。
  • 每例 targeting 1至4个(平均3个)renovisceral 分支血管进行开窗。
  • 平均住院时间19天(范围1-78)。
  • 30天内死亡1例,另有2例院内死亡。
  • 2例发生永久性脊髓损伤,2例发生呼吸衰竭,2例发生需要临时或永久透析的肾功能衰竭。

临床怎么用

  • 对于解剖不适合市售支架的高危复杂主动脉病变患者,医生改良开窗/分支支架可作为紧急治疗选择。
  • 需关注围术期脊髓损伤、肾功能衰竭及内漏等并发症。

局限性

  • 单中心回顾性研究,样本量较小(21例)。
  • 随访时间较短(平均11.2个月),且仅17例完成随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze the outcome of surgeon-modified fenestrated and branched stent-grafts (sm-FBSG) in high-risk patients with symptomatic complex aortic pathology or contained rupture. METHODS: A single-center retrospective analysis was conducted of 21 consecutive patients (mean age 70 years, range 58-87; 16 men) treated with a sm-FBSG from April 2014 to September 2016. The indications included 11 thoracoabdominal and 10 pararenal aortic pathologies, which presented as symptomatic in 8 and as contained rupture in 13 patients. The mean aneurysm diameter was 7.4±2.3 cm. RESULTS: Technical success was 100%. From 1 to 4 (mean 3) renovisceral branch vessels were targeted with fenestrations. The mean length of in-hospital stay was 19 days (range 1-78). There was 1 death within 30 days and 2 further in-hospital deaths. Two patients suffered permanent spinal cord injury, 2 developed respiratory failure, and 2 had renal failure requiring temporary or permanent dialysis. No myocardial infarction, stroke, or bowel ischemia occurred. Six early endoleaks (3 type II and 3 minor type III) were detected. Mean follow-up was 11.2 months (range 2-33) in 17 patients. One late aneurysm-related death occurred. All 13 follow-up imaging studies showed patent target renovisceral vessels, with 1 type I and 2 type II endoleaks. CONCLUSION: Sm-FBSG can be utilized for urgent treatment of complex abdominal and thoracoabdominal aortic pathologies in high-risk patients with anatomy unsuitable for commercially available stent-grafts.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Tsilimparis N, Heidemann F, Rohlffs F, et al. Outcome of Surgeon-Modified Fenestrated/Branched Stent-Grafts for Symptomatic Complex Aortic Pathologies or Contained Rupture. J Endovasc Ther. 2017. PMID: 28874089. doi:10.1177/1526602817729673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。